News from Zyme and the companies we work with.
Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker
Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled [...]
Newcells Biotech strengthens executive and US team with key appointments
Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced to meet [...]
Nuclera Awarded £1.14M Innovate UK Funding for Development of eProtein Discovery
£790k FASST grant, in collaboration with DeepMirror, and £350k Engineering Biology grant awarded for platform development Cambridge, UK, 06 June 2024: Nuclera, the biotechnology company accelerating protein expression and purification [...]
MediMab Biotherapeutics opens bespoke laboratory facilities, created by Kadans Science Partner, at Abingdon Science Park, UK
New CL2 wet lab purpose-built facilities delivered by Kadans Science Partner will support MediMab Biotherapeutics to identify first-in-class immuno-oncology drugs that can actively target a range of advanced and solid [...]
VALANX Biotech Announces Promising Results in First In-Vivo Study of Novel Protein Conjugate Therapy
Study demonstrates pre-clinical efficacy of lead program VLX101 in treating autoimmune disease Klosterneuburg, Austria, 05 June 2024: VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation [...]
Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows
Next-generation assay provides a rapid and cost-effective solution to quantify IgG production in single cells Cambridge, UK, 04 June, 2024: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for [...]
SolasCure Selected for Innovate UK Global Incubator Programme in Houston
Programme delivered in partnership with the Texas Medical Centre Programme will support Aurase Wound Gel for future entry into US market, advancing SolasCure’s mission to transform chronic wound care for [...]
PhoreMost Achieves Second Milestone in Target Discovery Alliance with Boehringer Ingelheim
Milestone payment follows successful target identification and validation in separate project under same collaboration Cambridge, UK, 03 June 2024: PhoreMost Ltd., has triggered a second milestone payment in its multi-project [...]
DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation
CAMBRIDGE and NEWCASTLE, UK, 03 June 2024: DefiniGEN Ltd., and Atelerix Ltd., today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma [...]
H.E.L Group extends sales and support with appointment of specialist distributors
Distributors will provide added application specific support for H.E.L’s biotechnology and chemical synthesis product portfolios in the USA, Spain and Portugal London, UK, 30 May 2024: H.E.L Group (H.E.L), a [...]
Cellular Origins and Cell and Gene Therapy Catapult collaborate to demonstrate universal automation of CGT manufacturing
Partnership to develop and implement Cellular Origins’ robotic platform Constellation for universal automation of CGT manufacturing at CGT Catapult’s Stevenage Manufacturing Innovation Centre CAMBRIDGE, UK, AND STEVENAGE, UK, 29 May [...]
Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics
Partnership expands spectrum of Secarna’s capabilities for the development of targeted ASOs beyond antibodies and sugar molecules New platform capabilities extend the reach of Secarna’s antisense approaches, potentially offering new [...]
